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Nontypable Haemophilus influenzae (NTHi) is a Gram-negative bacterium which causes 
otitis media (ear infections), pneumonia, bronchitis, and sinusitis. For many years, the P6 protein 
has been a leading candidate for a protein vaccine against NTHi, because it is conserved among 
NTHi strains, is believed to be surface exposed, and contains binding sites for specific 
antibodies. However, recent structural analysis suggests that P6 may be inserted into the outer 
membrane in two orientations. Based on the interaction with its homologues in Escherichia coli 
(E. coli), we proposed that P5, a transmembrane protein in NTHi, plays a role in P6’s apparent 
dual membrane orientation by either helping it to flip to the surface or by deceptively binding to 
P6 antibodies. Although the structure of the transmembrane region of P5 has been solved, the 
structure of the C-terminal end was not known until very recently. We attempted to use nuclear 
magnetic resonance (NMR) spectroscopy to solve the structure of the C-terminal end of NTHi 
P5, but the protein piece we engineered was most likely denatured or aggregated in solution. 
Also, flow cytometry experiments on the knockout of a P5 homologue, OmpA, in E. coli showed 
improved surface antibody binding to the P6 homologue, Pal: a contradictory result to our 
proposed hypotheses. Therefore, we discontinued our work with P5. A second goal of this work 
was to determine the epitope for the P6 antibody 4G4 through site directed mutagenesis, 
antibody binding assays, and NMR spectroscopy. Experimental results using the P6 T42E mutant 
showed no difference in antibody binding to 4G4 antibodies, suggesting that either the binding is 
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Infection by Nontypable Haemophilus influenzae and the role of P6 
 
 Nontypable Haemophilus influenzae (NTHi) is a nonencapsulated, Gram-negative, 
pathogenic bacterium that causes otitis media (ear infection), sinusitis, pneumonia, and other 
respiratory infections. Although there are cases of H. influenza infection in adults, NTHi 
infection is more common in children [1, 2, 3]. In the United States, 75% of children are 
diagnosed with at least one case of otitis media before their 3
rd
 birthday, and about half of those 
will experience three or more cases [1]. Otitis media is also the most common childhood illness 
for which pediatricians provide prescriptions [2, 3]. The creation of a safe and effective vaccine 
against NTHi would greatly reduce the occurrence of ear infections, protect against recurring 
cases, and also decrease the need for antibiotics.  
 A protein vaccine is one that contains a specific antigenic piece of protein(s), or whole 
protein(s) from the pathogenic agent rather than live or attenuated cells. The protein acts as a 
target for the immune response, but it does not have the ability to cause an infection on its own. 
In order for a protein to be considered a viable vaccine candidate, it must be surface exposed, the 
target of bactericidal antibodies, and preferably conserved among different pathogenic strains in 
order to provide broad protection. With NTHi, it has been difficult to create a protein vaccine 
because of the antigenic variability of the outer membrane proteins (OMPs) throughout the 
different strains [4]. Some previously studied NTHi proteins and potential vaccine candidates 
include OMPs P1, P2, P4, P5, P6, D15 and TbpA/B as well as some lipopolysaccharides (LPS) 





 For the past twenty years, the OMP P6 has been one of the leading vaccine candidates 
against NTHi [5-7]. It is a 16 kDa lipoprotein that is highly conserved among the different strains 
of NTHi, meaning that a P6 vaccine could potentially target most strains of NTHi. The P6 
protein also has homologues in other bacterial species, most notably the protein in Escherichia 
coli (E. coli) known as “peptidoglycan associated protein” or Pal [8-10]. The exact function of 
P6 has not yet been determined, but results from experiments performed on a P6 knock-out strain 
of NTHi suggest that it is important in maintaining the integrity/structure of the outer membrane 
[11]. The structure of a nonlipidated (NL) version of P6 (first 20 amino acids were deleted) 
bound to a peptdiglycan precursor has been solved using nuclear magnetic resonance (NMR) 
spectroscopy, and is shown in Figure 1.1 [12].  
 
Figure 1.1: The structure of nonlipidated NTHi protein P6 determined by NMR 
        spectroscopy. A fragment of peptidoglycan precursor is shown in red. [12] 
 
The P6 protein contains an N-terminal lipid anchor to the phospholipid bilayer of the membrane 
(not shown in Figure 1.1) as well as a region that interacts with the peptidoglycan in the 
periplasmic space. In vivo, the first 19 amino acids of the P6 sequence are removed prior to 
lipidation and the lipid anchor (a tripalmitoyl lipid motif) is attached the Cys residue at position 
20. P6 is also known to have at least three different monoclonal antibodies that bind specifically 





antibodies have been explored more recently [13,14]. Scientists have also demonstrated 
bactericidal activity of P6 antibdies [15]. Research performed by our collaborators at Rochester 
General Hospital Research Institute corroborates the hypothesis that P6 is a good vaccine 
candidate to protect against infection by NTHi [21, 22]. 
 
Verifying the surface exposure of P6 
 
Although much of the results from past studies strongly support the inclusion of P6 in an 
NTHi vaccine, there was still the issue of whether or not P6 was really surface exposed. For 
years it was widely accepted that P6 was surface exposed based on the results of an immuno-
gold antibody binding experiment [17, 18]. As shown in Figure 1.2, the immuno-gold 
experiment is a sandwich antibody binding assay where a primary antibody binds to its target, 
which must be a surface exposed protein (or molecule). The secondary antibody, which is 
conjugated to a gold label, targets the primary antibody, and therefore results in a signal when 
visualized by electron microscopy. However, after personal communication with the scientists 
who performed these experiments, we discovered that the NTHi cells were perforated prior to the 













Figure 1.2: The immuno-gold electron microscopy experiment. Only surface exposed 
proteins are able to bind the primary antibody and gold-labeled secondary 
antibody sandwich. When researchers visualized gold particles on the surface of 
NTHi cells using P6 antibodies, it was thought that P6 was indeed surface 
exposed [17].   
 
 
 The Michel lab used a combination of flow cytometry and confocal microscopy to further 
explore whether or not P6 was surface exposed [23]. Flow cytometry was used to detect 
fluorescent secondary antibody in an antibody sandwich assay similar to that shown in Figure 1.2 
(fluorescent tag on secondary antibody instead of gold label). Using all three P6 monoclonal 
antibodies as the primary antibody, it was verified that P6 was indeed surface exposed on whole 
NTHi cells [23]. The confocal microscope was then used to visualize P6 monoclonal antibodies 
bound to intact NTHi cells; images demonstrated that the cells were not damaged or dead (dead 
cells were stained using propidium iodide) [23]. The results of these two experiments confirm 
that P6 is indeed surface exposed.  
Since it is well known that P6 interacts noncovalently with peptidoglycan layer inside the 
cell [12, 5, 8], and we have verified that P6 is also surface exposed, it logically follows that P6 
would be a transmembrane protein. However, through the use of computational modeling, site-





small to be a transmembrane protein [14]. To explain this contradiction, two hypotheses were 
proposed: 1. There is non-P6 surface exposed protein with the same or very similar epitopes to 
P6 that can interact with P6 antibodies, or 2. P6 exists in two orientations, one inside the cell and 
able to bind peptidoglycan, and one outside the cell that is “flipped” through the membrane by a 
mechanism that is yet to be determined.   
To test the first hypothesis, the Michel lab performed simple experiments using cell 
lysates [23]. Specifically, a western blot of NTHi cell lysates showed that all three P6 
monoclonal antibodies (3B9, 4G4, 7F3) bind to only a single protein, and that no binding is 
shown on lysates from a P6 knockout NTHi strain [23]. These results refute the first hypothesis 
and indicate that the P6 monoclonal antibodies only bind to P6 and no other surface exposed 
protein. In addition, the results support that P6 exists in two orientations, as mentioned in the 
second hypothesis and depicted in Figure 1.3 below. 
 
 
Figure 1.3: Diagram that depicts the dual orientation hypothesis for NTHi protein P6. 
Here, the protein exists both in the periplasmic space, where it interacts with 
peptidoglycan, and on the surface of the cell, where it can be recognized by 
monoclonal antibodies. In both states the protein is tethered to the lipid bilayer by 





 As previously described, P6 is a member of the class of proteins known as peptidoglycan-
associated lipoproteins, and is therefore expected to localize within the periplasmic space [11]. 
This has been supported by the fact that purification of P6 from NTHi requires strong detergents 
or high temperatures [12, 35, 36]. Proteinase digestion experiments and flow cytometry 
performed by the Michel lab corroborate that P6 is internally localized [15]. Incomplete 
digestion of P6 in whole cells suggests that some of P6 was not accessible to Proteinase K 
activity, and flow cytometric analysis showed that only a small fraction (3-4%) of whole NTHi 
cells displayed detectable P6 on their surface, while a much larger percentage of cells (84.3%) 
expressed detectable P6 after they were permeabilized with 0.1% Triton X-100 [15].  
While these studies strongly support the dual orientation of P6 in NTHi (Figure 1.3), the 
protein cannot simply diffuse through the membrane lipid bilayer. Instead, a mechanism must 
exist to “flip” P6 from the periplasm to the cell surface. Such a mechanism might require a 
membrane channel that recognizes P6 and transports it to the cell surface, or a “flippase” protein 
that is capable of incorporating into the membrane and flipping P6 to the surface. Although this 
idea of a protein that is capable of having dual orientations in a cell is a fairly novel 
phenomenon, it has been described once before in the literature for the protein Lpp in 
Escherichia coli (E. coli) [32].  
E. coli are one of the most well studied and most utilized bacteria in science. The entire 
genome of E. coli has been sequenced, and E. coli can be easily manipulated to overexpress 
foreign protein using expression vectors/plasmids. Therefore, scientists often study bacterial 
proteins by expressing recombinant versions of the proteins in E. coli; we can also learn a lot 
about bacterial proteins by observing their homologues in E. coli. To test our hypothesis that a 





E.coli: Pal. Pal has been well studied by numerous scientists [24-30], and has been shown to 
interact with E. coli’s periplasmic protein TolB [29] and transmembrane protein OmpA [30]. The 
homologue of OmpA in NTHi is P5. OmpA is a large transmembrane protein that has a C-
terminal sequence similar to P6  [31]. The structure of the periplasmic C-terminal domain of 
OmpA was recenty determined, and as proposed, it is highly similar to the structure of P6 [19]. 
The sequence of OmpA is shown in Figure 1.4a. The P6-like domain of OmpA is located in the 
periplasmic space of E. coli and is known to interact with both Pal and peptidoglycan. 
Interestingly, the localization and configuration of the C-terminal end of OmpA is temperature 
dependent [16]. At increased temperatures (37 °C), the P6-like C-terminal end becomes 
integrated into the membrane, forming a larger transmembrane porin-like structure that likely 




















NGMLSLGVSYRFGQGE   AAPVVAPAPAPAPEVGTKHFTLKSDVLFNFNKATLK 
PEGQAALDQLYSQLSNLDPKDGVVVLGYTDRIGSDAYNQGLSERRAQSVVDYLI
SKGIPADKISARGMGESNPVTGNTCDNVKQRAALIDCLAPDRRVEIEVKGLDKD




Figure 1.4: a) The amino acid sequence of E. coli OmpA with the periplasmic domain  
highlighted in yellow, and b) a diagram of the irreversible temperature dependent 
folding transition that occurs with the C-terminal end (yellow) of OmpA 
[modified from reference 16]. 
 
This dramatic C-terminal folding transition could possibly explain how the Pal protein (or P6 in 
NTHi) is flipped to the surface of the outer membrane. We proposed that Pal (P6 in NTHi) 
interacts with OmpA (P5 in NTHi), which flips Pal to the surface via a “lasso-like” mechanism 
using its C-terminal tail. We did also entertain the hypothesis that OmpA itself (or in the case of 
NTHi, P5) mimicked Pal and interacted with Pal antibodies, thus leading us to the false 





in reference 23) demonstrated that P6 antibodies do not interact with proteins other than P6. 
Therefore, we limited our hypothesis to that in which OmpA “flips” P6 to the cell surface.  
 One useful technique to study proteins and protein function is the the use of a gene 
knockout, where the gene that codes for the protein of interest is made inoperative (turned off), 
and the protein is not expressed. We proposed that a gene knockout of P5 in NTHi could help us 
determine whether or not it is involved with the flipping of P6 to the cell surface. If P5 was 
responsible for flipping P6 to the cell surface, a P5 knockout would not allow P6 to be surface 
exposed.  However, as mentioned earlier, genetic engineering in E. coli is more easily 
accomplished than in NTHi, so we utilized an OmpA knockout in E. coli (a generous gift from 
Dr. Kwang Sik Kim, John Hopkins). Decreased antibody binding to surface exposed Pal in the E. 
coli OmpA knockout would strongly support our hypothesis that OmpA/P5 are involved in 
Pal/P6 surface exposure, necessitating further analysis. 
 
Identifying epitopes for P6 monoclonal antibodies 
 
 The identification of specific epitopes (binding sites) for monoclonal antibodies can 
provide a better understanding of the immune response to infection. In addition, epitopes for 
monoclonal antibodies are often highly “immunogenic” regions and can be used as a starting 
point in the design of peptides for protein vaccines. Using a protein to make a vaccine is ideal 
because it eliminates the possibility of infection from the application, which could occur with a 
vaccine made from an attenuated pathogen. By determining the specific antibody binding sites, 
or epitope mapping, we can sometimes determine the most immunogenic regions of the protein 





Previous studies have shown, through a competitive inhibition-enzyme linked 
immunosorbent assay (ELISA), that 4G4 and 7F3 compete for binding to P6 and thus share a 
similar or overlapping epitope while 3B9 has an independent binding site. Mapping of the 
epitope for 3B9 showed that its binding is dependent on two discontinuous regions of P6 that 
come together during the folding process [13]. Studies in the Michel lab have shown, through 
site-directed mutagenesis, that the binding of 7F3 is dependent on a single acidic residue at 
position 40 (Asp: aspartic acid). Since the epitopes for 4G4 and 7F3 overlap, we proposed that 
the epitope for 4G4 is close to Asp40, however, the exact binding site is unknown. Elucidating 
the epitope for 4G4 would tell us about the antibody/antigen interaction and provide information 
which could be used to create a peptide vaccine against NTHi. Peptides are easier and cheaper to 
produce than full-length proteins and therefore more attractive to vaccine companies.  
 
NMR Spectroscopy.  
 
 
 Nuclear magnetic resonance (NMR) spectroscopy is a technique used to analyze and 
determine the structure of a wide range of compounds from small organic molecules to complex 
folded proteins. The phenomenon of NMR utilizes the magnetic properties of specific atoms to 









an intrinsic property known as spin, and when placed in a magnetic field they absorb 
electromagnetic radiation at a characteristic frequency [33, 34].  NMR spectroscopy takes 
advantage of these properties by placing the sample of interest in a strong magnetic field and 
pulsing with radiofrequency (RF) energy. The nuclei absorb the RF radiation, align in the 
magnetic field, and give off specific and detectable energy as they relax back to equilibrium 





active nuclei. Chemical shift is calculated by comparing the resonant energy of the nuclei to a 
reference that is chemically unreactive (ex. tetramethylsaline) [34]. 
 Although one dimensional NMR analysis can provide enough information to determine 
the structure of a small organic molecule, protein analysis is best analyzed using two and three 
dimensional techniques. Heteronuclear single quantum coherence (HSQC) is a common 2D 
experiment used for protein NMR. By mapping the 
1
H chemical shift versus the 
15
N shift, the 
spectrum exhibits approximately one peak for the amide group of each residue. The unique fold 
of the protein results in a unique HSQC spectrum, thus resulting in its commonly used name the 
“fingerprint spectrum”. Many other 2D (and 3D) experiments can then be used to “assign” the 
peaks of the HSQC spectrum (ie, match each peak with its corresponding residue in the protein 
sequence). Further NMR experiments, often including 3D experiments and computational 
predictions, are required to determine the overall structure of a protein. After the structure of the 
protein is known, the applications of NMR expand. For example, if a change in conformation is 
induced upon the addition of a drug or peptide thought to interact with the protein of interest, the 
specific amino acids involved in the interaction can be tracked by changes in chemical shift. 
Titrating in a binding partner and tracking with NMR also allows for the calculation of binding 
affinities. Overall, NMR is a highly useful and powerful technique used to analyze proteins in 
solution. 
 
In summary, we proposed to assess the role of P5 in the “flipping of P6 to the cell surface and to 
identify the 4G4 binding site on P6. In the first part of our work, we set out to successfully 
express and purify the P6-like C-terminal domain of P5 and to determine its structure using 





us to determine the role of P5 in the surface exposure of P6. In the second part of our work, we 
set out to utilize site-directed mutagenesis and sandwich ELISA analysis to identify the P6 
epitope for the 4G4 antibody. If we could identify the most immunogenic regions of P6, it would 
be possible to create a vaccine using only that portion of the protein, which is more cost effective 
than using the whole protein and therefore highly attractive to the vaccine development industry. 























2.1 DNA Collection and Storage 
The DNA sequence that codes for the C-terminal amino acids of interest in protein P5 
were ordered from GeneArt (Invitrogen) in an ampicillin resistant DNA storage vector (puc19). 
A 6-histidine repeating tag was also added to the N-terminal end of the ordered sequence. The P5 
gene was subcloned into a kanamycin resistant pET28a bacterial plasmid expression vector 
(Breanna Kalmeta, Michel lab). The DNA plasmid was then transformed into competent XL1-
Blue (Agilent) and BL-21 (Invitrogen) E. coli cells using a standard heat shock protocol. Briefly, 
plasmid DNA was added to the competent cells and incubated on ice, heat shocked at 42 °C 
(XL1-Blue: 45 seconds, BL-21: 30 seconds), and super optimal broth with catabolite repression 
(SOC media) was added prior to a one-hour incubation at 37 °C (shaking). Cells were plated 
onto luria broth (LB) containing kanamycin and incubated at 37 °C overnight. 
 A single colony of bacteria from each plate was then added to 25 mL of LB (10 g NaCl, 
10 g tryptone, 5 g yeast extract, per 1 L) along with 25 µL of 50 mg/mL kanamycin and cultured 
at 180 rpm, 37 °C overnight. Glycerol stocks were prepared for each culture (900 µL of culture + 
100 µL of 80% sterile glycerol) and flash frozen in liquid nitrogen (stored at -80 °C). 
 The DNA was extracted and collected using a QIAprep plasmid DNA miniprep (5 mL) or 
midiprep (50 mL) kit (Qiagen). The 5 or 50 mL LB cultures were prepared using 5 or 50 µL of 
50 mg/mL kanamycin, respectively, and one colony from the LB plate. The cultures were 
incubated (180 rpm, 37 °C) overnight. The miniprep and midiprep protocols were followed as 
described by the manufacturer. DNA concentrations were calculated from OD values at 260 nm 






2.2 DNA Analysis 
Subcloned and transformed DNA was detected on an agarose gel (0.5 g agarose, 50 mL 
1X TAE: 4.84 g Tris, 1.14 mL glacial acetic acid, 2 mL 0.5 M EDTA, 2 µL ethidium bromide). 
Samples were prepared using 10 µL of the DNA and 2 µL of loading dye. The gel was run for 30 
minutes at 100 V until the tracking dye was about ¾ the way through the gel, and the DNA was 
visualized and photographed under UV-light. The DNA samples were also prepared for 
sequencing (2 µL T7 terminator primer, 1.5 ng DNA in water, final volume 18 µL) and sent to 
the Cornell University DNA sequencing facility. 
 
2.3 Protein Expression and Purification 
 The BL-21 cells containing the DNA plasmid of interest were cultured overnight (37°C) 
on an LB plate containing kanamycin (50 µg/mL). A single colony from the plate was used to 
inoculate a 25 mL LB overnight culture, supplemented with kanamycin (180 rpm, 37 °C). The 
25 mL starter culture was added to a 1 L solution of LB with 50 µg/mL kanamycin and 
incubated (140 rpm, 37 °C) until the culture absorbance at 600 nm reached about 0.6 (about 3 
hours). To induce protein overexpression, 0.250 g of isopropyl β-D-1-thiogalactopyranoside 
(IPTG) was added and the culture and allowed to incubate for three more hours. The cells were 
harvested via centrifugation (5000xg for 15 minutes at 4 °C) and stored at -20 °C overnight.  
 Culture pellets were thawed at room temperature for about 30 minutes and resuspended 
in 20 mL of equilibration buffer (50 mM Na2HPO4/NaH2PO4, 300 mM NaCl, pH = 7.0). The 
cells were sonicated for lysis (50 W) on ice for 15 minutes (15 seconds on, 45 seconds off), and 
centrifuged again at maximum speed (10,000 g) for 25 minutes at 4 °C. The pellet and an aliquot 





 The 6-Histidine-tagged protein of interest was purified using a Talon bead affinity 
column (Clontech) according to the manufacturer’s instructions. Approximately 3 mL of beads 
were added to a column, allowed to settle, and rinsed with 10 times the bed volume with 
equilibration buffer (above). The protein lysate was added to the column and allowed to rock at 
room temperature for one hour or overnight at 4 °C. Column flow-through was collected, and the 
column was rinsed with five times the bead volume of equilibration buffer. Elution buffer (50 
mM sodium phosphate buffer, 300 mM NaCl, 150 mM imidazole, pH = 7.0) was used to elute 
the protein of interest off the column. Samples were collected in 2.5 mL fractions, and protein 
was detected using UV-vis absorption spectroscopy (absorbance at 280 nm). To clean the 
column, five bead volumes of column cleaning buffer (20 mM MES, 0.1 M NaCl, pH = 5.0) was 
run through the column followed by five bead volumes of 20% ethanol. After about 3-5 uses, the 
columns were regenerated using 10 bead volumes of 0.2 M EDTA (pH = 7.0), 10 bead volumes 
double distilled water, 10 bead volumes 50 mM CoCl2, seven more bead volumes of water, and 
three bead volumes of 300 mM NaCl.  
 
2.4 Protein Analysis 
 Eluted protein fractions were combined and concentrated in a 50 mL Amicon filter (10 
kDa molecular weight cut off) centrifuge tube (5,000 g, 4 °C) to a final volume of  2.5-3.0 mL. 
The protein was exchanged into a final buffer (50 mM sodium phosphate buffer, 50 mM NaCl, 
pH = 7.0) using a PD-10 desalting column (GE Healthcare) according to the manufacturer’s 
instructions. The final protein concentration was calculated using a BCA assay (Pierce) 
performed according to the manufacturer’s instructions. Briefly, a BSA calibration curve was 





protein samples were incubated with the bicinchoninic acid whose colorimetric exposure is 
dependent on the protein concentration and length of exposure (562 nm). Protein sample 
concentrations were estimated using the BSA standard concentration curve. 
 The samples collected from the column were visualized using a 10% non-reducing SDS-
PAGE gel. (Separating gel: 3.27 mL 30% acrylamide/bisacrylamide, 3.33 mL Tris/sodium 
dodecyl sulfate (SDS) buffer pH = 8.0, 1.28 mL distilled water, 2.12 mL 50% glycerol, 100 µL 
ammonium persulfate (APS), 10 µL tetramethylenediamine (TMED), stacking gel: 405 µL 30% 
acrylamide/bisacrylamide, 775 µL Tris/SDS buffer pH = 8.0, 1.95 mL distilled water, 20 µL 
APS, 5 µL TMED). The gel apparatus was filled with 1X cathode buffer (6.06 g Tris, 8.96 g 
Tricine, 5 g SDS, 500 mL distilled water) inside the gel holder, and 1X anode buffer ( 12.1 g 
Tris, 500 mL distilled water, pH = 8.9) to the fill line in the apparatus. Samples were prepared 
and loaded onto the gel as described: 4 µL protein ladder and 10-12 µL of protein solutions (10 
µL of sample and 10 µL of 2X sample buffer: 25 mL 1M Tris-HCl pH 6.8, 2 g 2% SDS, 10 mL 
glycerol, 0.01 g bromophenol blue). The following samples were run on the gel to assess the 
purification protocol: cell pellet after lysis (resuspended in equilibration buffer), cell lysate, 
column flow-through, first wash, protein sample, and final wash from the column. The gel was 
run for ten minutes at 120 V and then for 45 minutes at 150-180 V. The gel was stained in 
Coomassie blue (200 mg Coomassie blue, 100 mL methanol, 20 mL glacial acetic acid, 80 mL 
distilled water) for one hour. The gel was then removed and rinsed in destaining solution (100 
mL methanol, 20 mL glacial acetic acid, 80 mL distilled water) for one hour, and stored in 







2.5 Site Directed Mutagenesis 
A QuikChange II kit (Agilent) was used to prepare the P6 T42E mutant (according to the 
manufacturer’s instructions). The forward and backward primers needed for the mutation were 
designed for optimal melting temperatures and ordered from IDT. 
Primers: 
T42E (ACT  GAA) 
Primer lengths: 68 nts 




 The plasmid DNA containing wild-type P6 was collected using a miniprep kit as 
previously described. The concentration of the DNA was estimated using the absorbance at 260 
nm and diluted to about 5 ng/µL in water. The primers were diluted to 50 ng/µL in water. To set 
up the mutagenesis reaction, 5 µL of 10X buffer reagent, 4 µL of wild type DNA, 4 µL forward 
primer, 4 µL backward primer, 1 µL dNTP, and 32 µL of water were added to a small thin-
walled tube.  After quickly/gently centrifuging down the solution, 1 µL of Pfu Ultra DNA 
polymerase was added, the tube placed in one of the thermalcycler wells, and the mutant 
program was run for a total of 2 hours (95 °C for 30 seconds, 55 °C for one minute, 68 °C for 5 
minutes, cycle 16 times). The sample was put on ice for about 2 minutes before 1 µL of Dpn 1 
enzyme was added. After another brief spin down in the centrifuge, the sample was incubated at 
37 °C in a water bath for about 1.5 hours. The Dpn-1 digested DNA was transformed into XL-1 
blue cells as described above (briefly, 50 µL cells thawed on ice were pipetted into a pre-chilled 
15 mL round bottom tube; 2 µL of the Dpn 1 digested DNA was added and the cells and 
incubated on ice for 30 minutes; cells were heat shocked at 42 °C for 45 seconds and placed on 





extract, 0.05 g NaCl, 1 mL 250 mM KCl, -brought to 100 mL with water and autoclaved, 0.5 mL 
syringe filtered 2M MgCl2, 2 mL 1 M glucose) was added to the cells which were then incubated 
(250 rpm, 37 °C) for one hour). The cell culture was plated in 250 µL, 200 µL, 100 µL, and 50 
µL aliquots onto separate kanamycin LB agar plates and incubated overnight at 37 °C. The 
colonies that grew on the plates were used to make glycerol stocks as previously described. The 
DNA was extracted from each culture as previously described and the mutation was confirmed 
by DNA sequencing at Cornell University.  
 
2.6 ELISA 
 A sandwich enzyme linked immunosorbant assay (ELISA) was performed using the P6 
wild-type and P6 T42E mutant protein samples. Both protein samples were diluted to 1 µg/mL 
and 0.5 µg/mL; 100 µL of the stock solutions were added to the wells of two rows (one row per 
sample) of a 96 well plate. The plate was incubated at room temperature for two hours and then 
at 4 °C overnight. The plate was washed 5 times with PBS/0.1% Tween wash buffer solution at 
room temperature, and blocked with 200 µL of blocking buffer (PBS/3 % skim milk/0.1 % 
tween) for one hour at 37 °C. After 5 more washes, 200 µL of a 1/10
th
 stock of 7F3 antibody was 
added to row A, and 200 µL of a 1/10
th
 stock of 4G4 was added to row E. 100 µL of blocking 
buffer were added to the remaining wells. A serial dilution was performed on the antibody (7F3: 
A to B to C; 4G4 E to F to G to H, with D serving as a blank). This pattern of addition is outlined 
below for a 96 well plate (Figure 2.1). The plate was incubated at room temperature for one hour 
and then washed five times; 100 µL of a 1/10,000 dilution of secondary antibody (goat anti-
mouse IgG HRP conjugate) was added to each well. The plate was incubated for one hour at 





plate was allowed to develop for 30 minutes in the dark, and the absorbances were recorded at 
450 nm using an absorption plate reader (BioTek).  
 
Figure 2.1: Diagram that explains what was added to each well of the 96 well plate for the 
ELISA experiment. Columns were filled with either 100 ng (wild type: 1,2 T42E: 5,6) or 
50 ng (wild type: 3,4 T42E: 7,8) of protein. The 7F3 antibody was diluted from rows  




The protein samples that were used for NMR spectroscopy were cultured in M9 minimal 
media (M9 salts: 34 g Na2HPO4, 15 g KH2PO4, 2.5 g NaCl, in 1 L distilled water, autoclaved; 
M9 minimal media: 200 mL M9 salts, 1 g 
15
NH4Cl, pH = 7.4, in 1 L distilled water – autoclaved 
and supplemented with 2 mL 1 M MgSO4, 100 µL 1 M CaCl2, 5 g glucose) with 
15
N-labeled 
ammonium chloride as its sole nitrogen source. The NMR sample was prepared with 50 µL of 
D2O and 450 µL of concentrated protein sample. All of the NMR experiments were run on a 
Bruker 500 MHz NMR spectrometer at 25 °C. A 1D 
1
H NMR spectrum was collected to confirm 




N HSQC (hsqcetgp experiment) spectrum was also 





“pulsecal” was used to auto calibrate the 90 degree pulse. The standard Bruker parameters were 
used with the following modifications: the attenuation level was changed to 2 dB, nucleus F1 
was set to 
15
N and the F2 channel was 
1
H, the nitrogen transmitter offset (nucleus O2P) was set 
to 120 ppm, gradient strength changed to 8.1 G cm
-1
, sweep width for F2 was 13 ppm and F1 
was 40 ppm, and the number of data points was 1024 and 256 with number of scans set to 8. The 
Bruker software was used to process the data and overlap the spectra of the wild-type protein 






















DNA sequencing was used to confirm that the correct coding sequence was being used 
during each experiment. The DNA sequence for the nonlipidated form of NTHi protein P6 is 
shown in Figure 3.1. The sequence for the P6-like C-terminal domain of NTHi protein P5, 
referred to as Sep5, is shown in Figures 3.2 and 3.3. Similarly, the DNA sequence for the P6 
T42E mutant is shown in Figure 3.4. For Figures 3.1, 3.3, and 3.4 the BamH1 (yellow) and Nco1 
(blue) restriction enzyme sites used to insert the sequence, and the histidine tag (red) used in 
protein purification are highlighted. Figure 3.2 traces the amino acid sequence coded for by the 
Sep5 DNA. All together, these results show that subcloning and site-directed mutagenesis were 
successful as determined by DNA sequencing analysis. 
Representative DNA and protein gels are shown in Figures 3.5-3.8, including protein gels 
for Sep5 and wild-type P6 and a protein and DNA gel for P6 T42E. Figure 3.5 is a Commassie 
blue stained SDS PAGE gel that contains samples collected during protein purification of Sep5. 
The Sep5 band (~16 kDa) is present throughout the process and is the only remaining band after 
the purification step. A similar purification process was performed for P6 and the P6 T42E 
mutant (P6 ~ 17 kDa, Figure 3.7). Figure 3.6 shows the Coomassie stained gel which includes 
samples from the Sep5 purification as well as the concentrated purified Sep5 samples that was 
used for NMR experiments (molecular weight standards omitted). The protein gels demonstrate 
that the protein of interest was present in the purified samples, and was the correct size when 
compared to the molecular weight standards used. The DNA gel in Figure 3.8 confirms the 
presence and correct molecular weight of purified DNA samples of the P6 T42E mutant which 





concentration of the NMR protein samples, as shown in Figure 3.9. The BCA assay allowed us 
to determine the protein sample concentrations for our NMR experiments (about 1 mg/mL). 
Figure 3.10 is the 1D proton NMR spectrum of the Sep5 sample. The NMR spectra did 
not show peaks to indicate the presence of folded protein (only water peak at 4.7 ppm). Figure 
3.11 shows the results of the flow cytometry experiment (Joy Snyder- Michel lab) performed on 
the E. coli OmpA knockout. Flow cytometry demonstrated that anti-Pal antibody does bind to the 
surface of the OmpA knockout cells (the anti-Pal surface stained cells are contained within the 
square inset and the percentage of stained cells is located above the inset). 
The proton NMR spectrum of the P6 T42E mutant is shown in Figure 3.12, and the 
presence of multiple peaks indicates folded protein. The overlapped HSQC NMR spectra of 
wild-type P6 and T42E mutant is shown in Figure 3.13 with no observable differences in 
chemical shifts for the peaks of the wild type (blue) or T42E mutant (red). The peaks in the 
HSQC spectra are spread out which confirms folded protein. This shows that the amino acids are 
interacting with a specific environment and are not all exposed to the solvent as in an unfolded 
protein, which would cause the peaks to be clustered and overlapping. The sandwich ELISA 
results for the P6 T42E mutant at 100 and 50 ng per well using 7F3 and 4G4 antibodies are 
shown in Figure 3.14 and 3.15. Both demonstrate a similar binding affinity of the proteins to 
both antibodies. The last two figures show DNA sequences for the P6 T42E mutant and the 
corresponding DNA chromatogram (Figure 3.16) and the DNA sequence of the P6 T42E mutant, 
which was verified after the ELISA and NMR data were collected (Figure 3.17). We repeated 
DNA sequencing on our samples to verify the presence of the mutation after collecting our data 































Figure 3.1: The reverse complement DNA sequence for nonlipidated P6 wild-type 
(top), and results from sequencing after subcloning ordered DNA into a pET28a 
vector and transforming into competent E.coli XL-1 blue cells (bottom). 
Highlighted are the BamH1 (yellow) and Nco1 (blue) restriction enzyme sites. 




















Gene name: NTHi_P5_C-term   1/10/2011    Geneart No:1100961 Gene length: 488 bp 
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Figure 3.2: The DNA (black) and amino acid (blue) sequence for the P6-like C-terminal end of  
P5, as ordered through Geneart (optimized for E.coli expression). Also shown, above the 



























Figure 3.3: The reverse complement DNA sequence for the P6-like C-terminal domain  
of P5, known as Sep5 (top), and results from sequencing after subcloning the 
DNA into the pET28a vector (bottom). Highlighted are the His tag (red), and 
BamH1 (yellow) and Nco1 (blue) restriction enzyme sites. Start and stop codons 

















































Figure 3.4: The reverse complement DNA sequence for the actual nonlipidated P6 (top), 
and results from sequencing of the T42E site-directed mutant, post QuikChange 
kit (bottom). Highlighted are the codes for threonine (gray) and glutamic acid 
(green) both at amino acid position 42 in the chain, the BamH1 (yellow) and 




























Figure 3.5: Protein gel with results from purification of two Sep5 E. coli BL-21 pellets.  
Lanes are from left to right: protein ladder (L), Sep5 BL-21 pellet after lysis and 
centrifugation (1), lysed solution added to column (2), column runoff (3), eluted Sep5 























































Figure 3.6: Image of a protein gel with lanes loaded from left to right: solution from  
Sep5 BL-21 after lysed and centrifuged (1), column runoff (2), eluted Sep5 
protein sample (3), a second lysed and centrifuged Sep5 BL-21 pellet (4), solution 
from lysed and centrifuged pellet (5), column runoff (6), eluted Sep5 protein 





































Figure 3.7: Images of protein gels with results from purification for, NL P6 BL-21 pellet (top)  
lanes are, from left to right: protein ladder (L), NL P6 BL-21 lysed solution added to 
column (1), column runoff (2), column rinse (3) (no visible bands), and eluted NL P6 
protein samples 1-5 (4-8 respectively). And P6 T42E BL-21 pellets (bottom) , loaded 
from left to right: protein ladder (L), P6 T42E lysed solution added to column (1), 
column rinse (2), P6 T42E protein samples 1-3 (3-5 respectively), a second P6 T42E 
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Figure 3.8: Image of a DNA gel loaded from left to right with DNA ladder (L), and 
miniprepped DNA samples from 6 growths of NL P6 T42E XL-1 blue E. coli 
cells. (plate A1-4 and plate B1-2 respectively). These samples were later sent for 
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Figure 3.9: Example of a standard curve (absorbance vs concentration) that was 
calculated using bovine serum albumin and used to better estimate the 
concentration of protein in our NMR samples. In this example the NL P6 
protein sample had an absorbance of 1.153, which corresponds to a 





















y = 0.0011x 

































Figure 3.10: The 
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Figure 3.11: Flow cytometry experiment results (performed by Joy Snyder of the  
Michel lab) of WT strain and OmpA knockout of E. coli. Two different antibodies 
that bind to Pal were tested: California antibody (gift from Dr. Judith Hellman – 
UC San Francisco) and France antibody (gift from Dr. Roland Lloubes – CNRS-
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Figure 3.13: a) Full scan and b) zoomed in shot of the overlapping HSQC NMR 
















Figure 3.14: The sandwich ELISA results for 7F3 antibody binding to the P6  
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Figure 3.15: The sandwich ELISA results for 4G4 antibody binding to the P6  
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Figure 3.17: The reverse complement DNA sequence for the actual nonlipidated P6  
(top), and results from a second sequencing of the P6 T42E mutant DNA after 
ELISA and NMR experiments were performed (bottom). Highlighted are the code 
for threonine (gray) and glutamic acid (green) both at amino acid position 42 in 
the chain, the BamH1 (yellow) and Nco1 (blue) restriction enzyme sites, and the 























4  Discussion 
 
4.1 Subcloning and mutagenesis 
 
 The truncated nonlipidated P6 was created by removing the first 19 amino acid residues 
from the N-terminal end of NTHi P6. Those residues make up the signal sequence which calls 
for the posttranslational addition of a lipid moiety that tethers the protein to the cell membrane; 
without the signal sequence the protein is more soluble and is folded (as seen by NMR), and 
hence easier to express and purify. Previous members of the Michel lab worked with the 
lipidated version of P6 (maintaining the first 19 amino acids), but the protein aggregated and/or 
unfolded readily (as seen with NMR spectroscopy). Therefore, all wild-type and mutant P6 
proteins described in this thesis were nonlipidated.  
 The gene containing the C-terminal P6-like domain of P5 (named “Sep5”) was 
synthesized by the GeneArt Company (Invitrogen) and placed into a puc19 vector (Figure 3.2). 
Once received, the Michel lab subcloned the Sep5 gene into pET28a vector containing a LacZ 
overexpression promoter region. The P6 sequence aligns relatively closely to the OmpA 
sequence with 27.4% identical and 58.2% similar amino acids, and most of the homology 
occurring at the C-terminal end of OmpA (Figure 4.1). Also, a recent structure of the C-terminal 
end of OmpA (P5 homolog in E. coli) confirms that the structure is similar to that of P6. A 
comparison of the structures of NTHi P6 and the C-terminal end of an OmpA protein are 







Figure 4.1: The BLAST protein sequence alignment of NTHi P6 (P10324) and E.coli  
OmpA (P0A910). Matching amino acid residues are marked with an asterisk and 
similar amino acids with dots. The sequences are 27.4% identical (42/153) and 






Figure 4.2: Protein structures of NTHi P6 (PDB ID: 2AIZ), left, and C-terminal tail of 
 OmpA from Acinetobacter Baumannii (PDB ID: 3TD4), right. Alpha helices are 






 Confirming correct DNA sequences was an important part of each phase of this project. 
All genes encoding for our proteins of interest were subcloned into pET28a vectors, which were 
transformed into both E. coli XL-1blue cells (for DNA storage) and BL-21 cells (for protein 
expression). There were three different proteins used throughout the course of this study. The 
wild-type nonlipidated P6 was used, since the lipidated version of P6 did not fold properly and 
was not easily purified, as determined through NMR analysis [14]. The sequencing results for 
Sep5 confirmed that the designed C-terminal end of P5 did subclone correctly into the pET28a 
vector (Figure 3.3). Also, after several failed attempts, site-directed mutagenesis was successful, 
resulting in creation of the P6 T42E mutant (Figure 3.4). Mutagenesis was re-confirmed prior to 
experimentation on P6 T42E (Figure 3.16 and 3.17). 
 DNA sequencing results received from the Cornell Life Science Core Laboratories 
Center included a DNA chromatogram (Figure 3.16) of the DNA bases on the reverse strand of 
DNA. Occasionally the program could not decipher which base was present at a specific location 
and would simply enter an “N” in the sequence. Although it was tedious, all of the “N”s were 
found in the chromatogram to determine if there was a mistake in the sequencing or in the DNA 
itself. There were occasional point mutations, but all were contained within the “wobble” base, 
so the correct amino acid sequence was maintained.  
 The first few attempts at creating the P6 T42E mutant were not successful. After further 
analysis, we realized we were not using enough wild-type DNA (likely due to a miscalculation of 
the original DNA concentration). After correcting for this error, the QuikChange II site-directed 








4.2 Protein and DNA Gels 
The purification process we used did successfully isolate our proteins of interest, but the 
yields varied between proteins. The yield of the Sep5 protein was significantly lower than both 
the wild-type (WT) P6 and P6 T42E mutant. This difference can be seen by comparing the 
intensity of the protein sample bands for Sep5 (Figure 3.5) and both P6 gels (Figure 3.7). The 
absorbance of the collected samples also reflected this difference, with P6 often reaching an 
absorbance around 0.2 while Sep5 barely reached 0.02 at 280 nm. We made several attempts to 
optimize the culture conditions and protein expression levels: varying culture temperatures and 
timing of induction, sonication times, and the addition of surfactant to the lysis buffer. In an 
effort to decrease protein loss in the column flow through (Figure 3.5), we increased the 
incubation time of the beads with our lysate (to overnight). Although the Sep5 protein was no 
longer in the column flow through (Figure 3.6), yields remained significantly lower than those of 
wild-type P6. We did, however, make up for the low yields by repeating the 
expression/purification process many times. 
The purification and collection of both WT P6 and P6 T42E was much more successful. 
The proteins were easy to isolate and eluted in high concentrations (Figure 3.7). The DNA gels 
(Figure 3.8) were used mostly to confirm the presence of DNA before samples were sent off for 
sequencing (after mutagenesis). Although all of the samples in Figure 3.8 were sent for 
sequencing, the DNA for sample A1 matched the P6 T42E mutant perfectly and was used to 








4.3 Sep5 Analysis 
 Typically, an ideal protein sample for NMR experiments has a concentration between 
0.5-1.0 mM (or higher). After many rounds of expression and purification, the Sep5 protein 
samples were concentrated and exchanged into the appropriate buffer; we attempted an initial 1D 
1
H NMR experiment on the sample. We initially ran the sample under the basic hydrogen 
experiment parameters, but we saw no peaks indicating the presence of protein. In our second 
trial we ran the same 1D 
1
H experiment but used an automated water suppression program called 
“Watergate” to try and minimize interference from the water signal. However, as shown in 
Figure 3.10, there were still no visible protein peaks. We also ran the NMR protein sample on a 
gel (Figure 3.6) and were able to visualize a pronounced band at the correct molecular weight for 
Sep5. Therefore, we knew Sep5 protein was present in the sample; we concluded that Sep5 was 
denatured or aggregated and therefore undetectable in NMR spectroscopy. If a protein becomes 
denatured or aggregated, its molecules will experience the same or very similar chemical 
environment. This in turn disrupts the signal that would be seen in an NMR spectrum, especially 
when looking at an HSQC spectrum of a protein. In a folded protein, each amino acid has a 
specific chemical environment around it, which determines its chemical shift and location on an 
HSQC spectrum. If the amino acids are seeing very similar or the same chemical environment, 
the peaks would all be grouped in a single location and not widely distributed in the spectrum (as 
would be the case for a disordered or unfolded protein).  
 Rather than continue to work out the problems of isolating the Sep5 protein, we decided 
not to pursue the project further due to the initial NMR results and new information from other 
experiments. Our original hypothesis was that the NTHi P5 protein was involved in flipping P6 





homologue) surface antibody binding test on an OmpA (P5 homologue) knockout using flow 
cytometry (Figure 3.11). In flow cytometry, cells are passed through a laser beam one at a time; a 
detector differentiates between whole cells and debris and between fluorescently labeled and 
unlabeled cells. The samples were prepared using a basic antibody sandwich where the primary 
antibody (Anti-Pal) bound to surface exposed protein in whole cells and a secondary antibody 
conjugated to a fluorescent tag binds to the primary antibody (similar to Figure 1.2). Labeled 
cells are shifted up away from unlabeled cells in the flow output plot. The results of the 
experiment (Figure 3.11) show that Pal antibodies bind just as well and even slightly better to an 
OmpA knockout cell (where OmpA in not expressed) compared to WT cells. We would predict 
that if OmpA played an important role in flipping Pal to the cell surface of E. coli, we would not 
see Pal on the surface of OmpA knockout cells. Therefore, the results of flow experiments 
suggest that OmpA is not involved in the surface exposure of Pal. Due to this finding, and our 
difficulty in obtaining folded Sep5, we decided to discontinue our work on OmpA/P5. 
 
4.4 Mapping of the 4G4 Epitope 
As previously mentioned, the 4G4 and 7F3 antibodies to NTHi P6 are known to compete 
for similar binding sites. It was shown, in the Michel lab, that a single mutation at position 40 
(D40N) greatly reduced 7F3 binding. This would indicate that the 4G4 epitope is in a nearby 
region to residue 40. We decided to create a T42E (threonine to glutamic acid) mutant and test 
for changes in 7F3 and 4G4 binding.  
Although we confirmed the sequence results for the mutant, it was also important to 
compare the structure of the P6 T42E mutant to wild-type P6 to ensure that the overall tertiary 







N-labelled ammonium chloride in M9 minimal media. To prepare the samples for NMR, 
the protein was concentrated and exchanged into the final buffer, as described above. A BCA 
assay was also performed to estimate the concentrations of the protein samples.  
We once again started by collecting a 1D 
1
H NMR spectrum, and this time we did see 





N HSQC “fingerprint” spectrum for WT and mutant proteins, and overlapped 
the spectra as shown in Figure 3.13. In a 2D HSQC spectrum, each 2D peak represents the amino 
group of a specific amino acid in the protein sequence. The position (or frequencies) of these 
peaks are very sensitive to the local and global structure of the surrounding environment within 
the protein. By overlapping the spectra from the P6 T42E (pink/red) and wild type (blue/light 
blue) we can clearly see that there is only a very small difference between the two proteins. The 
differences in the spectra that are noticeable are most likely due to the mutation itself or small 
local changes resulting from the mutation. We concluded that the tertiary structure of the T42E 
mutant remained highly similar to that of wild-type P6. 
In the ELISA, we tested two different concentrations of our proteins (T42E and WT) for 
binding to P6 antibodies 4G4 and 7F3. The results for 4G4 binding did not vary significantly 
between wild-type and the T42E mutant at either concentration, although the mutant did show a 
slightly higher absorbance in the 50 ng per well assay (Figure 3.15). Interestingly, the 7F3 
antibody did show a reasonably higher absorbance in the T42E mutant, indicating that the T42E 
mutant has a higher binding affinity for 7F3, compared to WT P6 (Figure 3.14). This suggests 
that although 7F3 binding is mediated by the aspartic acid residue at position 40, the amino acid 
at position 42 may also play a role in binding. With two acidic residues in position 40 and 42 (in 





amino acids in the 7F3 binding site. In comparison, residue 42 does not seem to affect P6 
binding to 4G4 at all. We propose that residue 42 is not part of the P6 epitope for 4G4 or that a T 
to E mutation does not affect binding of 4G4 to P6. However, we are currently testing a different 






















5 Conclusions and Future Directions 
 In conclusion, the results of our flow cytometry experiments with the E. coli OmpA 
knockout indicate that OmpA does not play a significant role in the surface exposure of Pal. 
Based on these results, we believe that it is unlikely that P5 is involved in the surface exposure of 
P6 in NTHi. Since our C-terminal fragment of P5 (Sep5) was not detected via NMR, and in light 
of our flow results, we decided to discontinue work on our P5/OmpA hypothesis. However, the 
recent structure of the C-terminal end of OmpA confirms our hypothesis that its structure is 
highly similar to that of P6 [19]. 
 Although the results of P6 T42E ELISA showed no significant change in P6 binding to 
the mutant, there are other avenues that should be explored to identify the 4G4 epitope. Perhaps a 
more significant mutation at position 42, such as from threonine to arginine (T42R) could 
demonstrate whether residue 42 is essential for 4G4 binding. Also, further examination of the 
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